In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on Charles River Laboratories CRL with a Buy rating and $56.00 price target.
In the report, Sterne Agee noted, “In our view, CRL can be characterized as a dominant player within businesses that possess high barriers to entry. With innovative product and service offerings offered at competitive prices, we believe large biopharmaceutical companies seeking to variable-ize cost structures will look to CRL as a provider of choice. We are re-initiating coverage of CRL with a Buy rating and $56 price target.”
Charles River Laboratories closed on Tuesday at $42.27.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.